Tissue Regenix Group PLC Appointment of CFO (3280K)
August 28 2019 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3280K
Tissue Regenix Group PLC
28 August 2019
Tissue Regenix Group plc
Appointment of CFO
Leeds, 28 August 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or the "Group"), the regenerative medical devices company,
announces the appointment of Mike Barker as Chief Financial Officer
(CFO). Mike will join the Group as CFO and as an Executive Director
on the Board with immediate effect having supported Tissue Regenix
since the beginning of the year as interim Finance Director.
A Chartered Accountant for over 20 years, Mike has experience of
both AIM listed and private businesses. After training with
Deloitte, he spent 10 years in their corporate finance advisory
business working extensively on private equity transactions before
setting up his own consultancy business to assist SME's in the
delivery of their strategic plans. During this time, he worked
closely with the management team of Quantum Pharma plc, a UK
manufacturer and supplier of unlicensed medicines and
hard-to-source products (acquired by Clinigen Group plc in 2017),
to deliver strategic projects before holding the position of Group
Corporate Development Director.
Full details of Mike's current and past directorships are
provided below.
John Samuel, Executive Chairman, Tissue Regenix Group plc,
commented:
"It's a pleasure to welcome Mike to the Executive team. He is
well acquainted with the business, having supported the Group since
the beginning of the year. His experience in AIM listed businesses
and contribution to strategic planning will augment and strengthen
our management and Executive teams as we continue to improve the
efficiency of our operations across the business to meet the
increasing demand for our products."
For more information:
Tissue Regenix Group plc Tel: 0330 430 3073 / 07920272441
Caitlin Pearson, Head of Communications
------------------------------------------ ---------------------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben
Maddison
------------------------------------------ ---------------------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Victoria Foster Mitchell
/ Mary Whittow
========================================== =================================
Regulatory disclosures
Michael (Mike) Denis Barker, aged 43
Current directorships: Directorships in the last 5
years:
TimeC 1306 Limited Quantum Pharma Group Limited
Barker Advisory Limited Quantum Pharmaceutical Limited
Rhythm Time (Newcastle) LLP Nupharm Laboratories Limited
Cambridge Scholars Publishing Nupharm Group Limited
Ltd
Ridge Pharma Ltd
There is no further information to be disclosed in accordance
with the requirements of Schedule Two paragraph (g) of the AIM
rules.
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPGUWWRUPBGRM
(END) Dow Jones Newswires
August 28, 2019 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024